Pharma and Biotech stocks News; BioSante Pharmaceuticals, Inc. To Present at BioCentury and BIO Healthcare Conferences

LINCOLNSHIRE, Ill. - October 17, 2011 (Investorideas.com newswire) - BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) today announced that Stephen M. Simes, BioSante's president & CEO will present at two healthcare conferences in October. Mr. Simes will speak at the BioCentury NewsMakers in the Biotech Industry on Friday, October 21 at 11:30 am EDT in New York and at the BIO Investor Forum on Tuesday, October 25 at 3:30 pm PDT in San Francisco.

BioSante will provide a company overview at each conference, as well as an update on the LibiGel (testosterone gel) Phase III clinical development program and planned new drug application (NDA) submission.

A live audio webcast of remarks by Mr. Simes, at the BioCentury conference may be accessed at http://www.corporate-ir.net/ireye/ conflobby.zhtml?ticker= BPAX&item_id=4209619. A live audio webcast of remarks by Mr. Simes, at BIO Investor Forum may be accessed at http://www.veracast.com/webcasts/ bio/ investorforum2011/16113461.cfm. Both webcasts will be archived for 90 days.

About BioSante Pharmaceuticals, Inc.

BioSante is a specialty pharmaceutical company focused on developing products for female sexual health and oncology. BioSante's lead products include LibiGel® (transdermal testosterone gel) for the treatment of female sexual dysfunction (FSD) which is in Phase III clinical development under a U.S. Food and Drug Administration (FDA) Special Protocol Assessment. BioSante also is developing a portfolio of cancer vaccines, four of which have been granted Orphan Drug designation, and are currently in several Phase II clinical trials. Other products in development are Bio-T-Gel™, a testosterone gel for male hypogonadism licensed to Teva Pharmaceuticals and an oral contraceptive in Phase II clinical development using BioSante patented technology. The company also is seeking opportunities for its other technologies. Additional information is available online at: www.biosantepharma.com.

Contact:

BioSante Pharmaceuticals

For Investors: The Trout Group LLC Tricia Swanson (646) 378-2953 tswanson@troutgroup.com

or

For Media: Harris D. McKinney, Inc. Alan Zachary, 312-506-5220 azachary@harrisdmckinney.com

BioSante Pharmaceuticals, Inc: (NASDAQ: BPAX) is a featured showcase biotech/pharma stock on Investorideas.com

Request news, updates and trading alerts on BPAX and other showcase stocks http://www.investorideas.com/Resources/Newsletter.asp

Research more biotech stocks at the Biotech stocks Directory: http://www.investorideas.com/BIS/Stock_List.asp

About InvestorIdeas.com:

InvestorIdeas.com is a leading global investor and industry research resource portal specialized in sector investing, covering leading industry sectors including biotech and pharma stocks.

Disclaimer: The following news/content is paid for as part of the BPAX showcase program (two thousand per month) Investorideas.com is a third party publisher of news and research Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising.

Investorideas.com Disclaimer: http://www.investorideas.com/About/Disclaimer.asp

Investorideas.com Disclosure: http://www.investorideas.com/About/News/Clientspecifics.asp

Source: Investorideas.com, BioSante, Investorideas.com

800 665 0411 cvanzant@investorideas.com